Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$4.61
Change (%) Stock is Down 0.06 (1.28%)
Volume127,638
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
08/09/18ChromaDex Corporation Reports Second Quarter 2018 Financial Results   
Second Quarter 2018 Net Revenues Increased by 85% to $7.8 Million IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today second quarter 2018 financial results. Second Quarter 2018 Highlights vs. Second Quarter 2017 Net sales up 85%, fueled by growth of TRU NIAGEN®; TRU NIAGEN sale... 
Printer Friendly Version
08/08/18ChromaDex to Launch TRU NIAGEN® in New Zealand with Retail Partner Matakana SuperFoods
TRU NIAGEN® expands presence in Asia-Pacific region with entry into New Zealand IRVINE, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the appointment of Matakana Superfoods (MSF) as the exclusive distributor of TRU NIAGEN in New Zealand. The sole active ingredient in TRU NIAGEN is nicoti... 
Printer Friendly Version
08/07/18ChromaDex and Watsons Expand TRU NIAGEN® Retail Partnership Through 2021
Global partnership commits to significant growth of TRU NIAGEN® including launch in Turkey IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the expansion of its partnership with A.S. Watson Group until September 2021, as well as plans to launch TRU NIAGEN in Watsons Turkey in late 2018... 
Printer Friendly Version
What's New
DateTitle
08/09/18
Q2 2018 Earnings Presentation PDF
07/17/18
July 2018 Investor Presentation PDF
08/09/18
2018 Q2 Quarterly Report on Form 10Q PDF
04/27/18
2018 Proxy Statement  PDF
03/15/18
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.